InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+62.2%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Almenoff June Sherie, 董事. Director active across 4 companies, notably Brainstorm Cell Therapeutics INC.. Aggregated, 7 disclosures have been published. Split: 3 buys · 0 sell. Total volume traded: €7k. History available since 10 December 2021. The latest transaction was disclosed on 2 September 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Almenoff June Sherie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
18,000 股0Common StockSEC:0001213900-26-097742:0
93 股@ US$7.1550.0% 占其流量Common StockSEC:0001492647-25-000004:0
标准退出：2026年2月15日 (T+90)
93 股@ US$7.1550.0% 占其流量Common StockSEC:0001492647-25-000003:0
标准退出：2026年2月15日 (T+90)
3,167 股Common StockSEC:0001578563-25-000199:0
500 股@ US$12.499100.0% 占其流量Common StockSEC:0001578563-24-000441:0
标准退出：2025年2月10日 (T+90)
2,000 股0Common StockSEC:0001104659-21-151214:0
2,000 股0Common StockSEC:0001104659-21-148745:0
7 条申报中的 7 条
About Almenoff June Sherie
Almenoff June Sherie is an Administrateur at Tenax Therapeutics, INC., Avalo Therapeutics, Inc. and Brainstorm Cell Therapeutics INC. The record shows 6 filings in total, and in the recent filings tracked, acquisitions run from 2021-12-10 to 2025-11-20, with EUR 7005 of buys and EUR 0 of sells.
